---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-032599"
form_type: "8-K"
ticker: "RNGE"
cik: "0001438943"
company_name: "RANGE IMPACT, INC."
filed_at: "2021-12-28T23:59:59+00:00"
generated_at: "2026-06-27T22:06:20.590538+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Malachite Innovations announces two USPTO patents granted for cannabinoid prodrugs and antimicrobials; new PCT filing

## Summary
- U.S. Patent granted for 'Cannabinoid Glycoside Prodrugs and Methods of Synthesis' covering 18 distinct cannabinoid glycosides for treating IBD and IBS.
- Second U.S. Patent granted for 'Antimicrobial Composition Comprising Cannabinoids' covering CBD/THC against C. diff, VRE, and S. pneumoniae.
- New PCT patent application filed for 'Continuous Enzymatic Perfusion Reactor System' to improve glycoside manufacturing; preserves rights in 153 countries.
- Patents based on 2016 and 2018 PCT filings, solidifying company's pioneer position in cannabinoid prodrugs without psychoactive effects.
- Subsidiary Graphium Biosciences holds patents; additional divisional applications are being pursued.

## SEC filing metadata
- accession: 0001493152-21-032599
- form_type: 8-K
- ticker: RNGE
- cik: 0001438943
- company_name: RANGE IMPACT, INC.
- filed_at: 2021-12-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438943/000149315221032599/0001493152-21-032599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438943/000149315221032599/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-032599
- JSON: https://secwatch.observer/filing/0001493152-21-032599.json
- Plain text: https://secwatch.observer/filing/0001493152-21-032599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.